Digital Support for Multiple Myeloma Quality of Life
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Digital support.
- Who it may be relevant to
- Registry conditions: Multiple Myeloma, Patient Reported Outcome (PRO), Supportive Care in Cancer, Quality of Life. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Greece
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Digital Support for Enhancing the Quality of Life of Patients With Multiple Myeloma: An Observational, Randomized, Prospective Study (DigiMyQoL)
Overview
The objective of this prospective study is to investigate the quality of life of patients with multiple myeloma and the effectiveness of support provided through a personalized web-based platform. Specifically, the study will compare Patient-Reported Outcomes (PROs) and the associated improvement in side effects and quality of life achieved through appropriate personalized educational and supportive content.
Interventions
- Behavioral Digital support
Personalized educational and supportive material, based on each patients' adverse events reported as PROs, delivered via the online platform.
Primary outcome measures
- Patient Reported Outcomes (PROs) [Time frame: From enrollment, until study completion, average 1 year.]
Secondary outcome measures (2)
- Progression-Free Survival [Time frame: At 12 months from each patient's enrollment]
- Overall Survival [Time frame: At 12 months from each patient's enrollment]
Eligibility criteria
Inclusion criteria
- Adult patients with newly diagnosed or relapsed/refractory multiple myeloma
- Patients that are able to use the digital platform/application
Exclusion criteria
- Patients that are not able to use the digital platform/application
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Supportive care
Study locations
Greece · 1 center
- Alexandra General Hospital — Athens
Identifiers
NCT: NCT07642362 · 160/27022025